this article describes the pharmacokinetics of 2',3'-dideoxyadenosine ( dda ) and 2',3'-dideoxyinosine ( ddi ) as determined during phase i clinical trials in patients with acquired immunodeficiency syndrome and acquired immunodeficiency syndrome-related complex .
C0012133
ddi
C0001175
acquired immunodeficiency